NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

體抑素瘤:至2030年的流行病學預測

Somatostatinoma - Epidemiology Insight - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966820
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
體抑素瘤:至2030年的流行病學預測 Somatostatinoma - Epidemiology Insight - 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供美國、德國、法國、義大利、西班牙、英國,與日本的主要7個國家的體抑素瘤的流行病學與相關市場調查,疾病的背景和概要,流行病學患者數,目前治療方法,主要的專家的見解,未滿足需求等資訊。

目錄

第1章 主要調查結果

第2章 摘要整理

第3章 疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第4章 病患歷程

第5章 流行病學和患者數

  • 主要調查結果
  • 前提和根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 主要7個國家的流行病學情況
  • 美國
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 治療流程,目前治療和醫療

  • 治療和管理
  • 治療流程

第7章 主要專家的見解

第8章 未滿足需求

第9章 附錄

  • 參考文件
  • 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1095

DelveInsight's 'Somatostatinoma - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Somatostatinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Somatostatinoma Understanding

The DelveInsight Somatostatinoma epidemiology report gives a thorough understanding of the Somatostatinoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Somatostatinoma in the US, Europe, and Japan. The report covers the detailed information of the Somatostatinoma epidemiology scenario in seven major countries (US, EU5, and Japan).

Somatostatinoma Epidemiology Perspective by DelveInsight

The Somatostatinoma epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Somatostatinoma epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Somatostatinoma epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Somatostatinoma Detailed Epidemiology Segmentation

The Somatostatinoma epidemiology covered in the report provides historical as well as forecasted Somatostatinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Somatostatinoma report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Somatostatinoma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Somatostatinoma Epidemiology Report and Model provide an overview of the risk factors and global trends of Somatostatinoma in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Somatostatinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Somatostatinoma
  • The report provides the segmentation of the Somatostatinoma epidemiology

Report Highlights:

  • 11-Year Forecast of Somatostatinoma epidemiology
  • 7MM Coverage
  • Total Cases of Somatostatinoma
  • Total Cases of Somatostatinoma according to segmentation
  • Diagnosed cases of Somatostatinoma

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Somatostatinoma ?
  • What are the key findings pertaining to the Somatostatinoma epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Somatostatinoma across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Somatostatinoma ?
  • What are the currently available treatments of Somatostatinoma ?

Reasons to buy:

  • The Somatostatinoma Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Somatostatinoma market
  • Quantify patient populations in the global Somatostatinoma market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Somatostatinoma therapeutics in each of the markets covered
  • Understand the magnitude of Somatostatinoma population by its epidemiology
  • The Somatostatinoma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Somatostatinoma

3. Somatostatinoma : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Somatostatinoma Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Somatostatinoma Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Somatostatinoma Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Somatostatinoma Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Somatostatinoma Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Somatostatinoma Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Somatostatinoma Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Somatostatinoma Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Somatostatinoma Treatment and Management
  • 6.2. Somatostatinoma Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Somatostatinoma Epidemiology in 7MM (2017-2030)
  • Table 2: Somatostatinoma Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Somatostatinoma Epidemiology in the United States (2017-2030)
  • Table 4: Somatostatinoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Somatostatinoma Epidemiology in Germany (2017-2030)
  • Table 6: Somatostatinoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Somatostatinoma Epidemiology in France (2017-2030)
  • Table 8: Somatostatinoma Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Somatostatinoma Epidemiology in Italy (2017-2030)
  • Table 10: Somatostatinoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Somatostatinoma Epidemiology in Spain (2017-2030)
  • Table 12: Somatostatinoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Somatostatinoma Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Somatostatinoma Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Somatostatinoma Epidemiology in Japan (2017-2030)
  • Table 16: Somatostatinoma Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Somatostatinoma Epidemiology in 7MM (2017-2030)
  • Figure 2: Somatostatinoma Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Somatostatinoma Epidemiology in the United States (2017-2030)
  • Figure 4: Somatostatinoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Somatostatinoma Epidemiology in Germany (2017-2030)
  • Figure 6: Somatostatinoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Somatostatinoma Epidemiology in France (2017-2030)
  • Figure 8: Somatostatinoma Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Somatostatinoma Epidemiology in Italy (2017-2030)
  • Figure 10: Somatostatinoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Somatostatinoma Epidemiology in Spain (2017-2030)
  • Figure 12: Somatostatinoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Somatostatinoma Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Somatostatinoma Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Somatostatinoma Epidemiology in Japan (2017-2030)
  • Figure 16: Somatostatinoma Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report